Novo A/S (Novo Holdings) / Xellia Pharmaceuticals

Hospital-Acquired Gram-Negative and Resistant Gram-Positive Infections (specialty injectable anti-infectives)

$1.9B Global daptomycin market 2024 (~USD 1.89B); global vancomycin ~USD 2.8-3.2B by 2025

Disease Overview

Xellia's portfolio addresses life-threatening hospital-acquired infections caused by methicillin-resistant Staphylococcus aureus (MRSA), enterococci, and multidrug-resistant Gram-negative organisms (including Pseudomonas and Acinetobacter). Vancomycin remains the workhorse for MRSA, daptomycin a critical alternative for vancomycin-resistant strains, and colistimethate is increasingly used as a last-line salvage agent against carbapenem-resistant Gram-negatives.

Competitive Landscape

The hospital anti-infective specialty/generic injectable market in 2013 was dominated by branded leaders Cubicin (daptomycin, Cubist), Zyvox (linezolid, Pfizer), Vibativ (telavancin, Theravance), and Pfizer's branded vancomycin (Vancocin) — with a deep generic injectables tier supplied by Hospira, Sandoz, Mylan, Fresenius Kabi, and Xellia itself. Xellia's positioning was distinctive: it was a vertically integrated fermentation-based API and finished-dose-form manufacturer, holding leadership share in vancomycin and colistimethate APIs globally and adding daptomycin capacity ahead of the 2016 Cubicin patent cliff. For Novo A/S, the ~$700M take-private from 3i was strategically explicit — CEO Henrik Gürtler called it 'one of the largest investments made by Novo A/S to date' and tied it to Novo's fermentation-technology thesis already represented by Novo Nordisk, Novozymes, and Chr. Hansen. The thesis paid off as Xellia became a key Civica Rx partner (2019) supplying generic vancomycin and daptomycin to address chronic US hospital shortages, validating Novo's long-hold view that resistance-driven, low-margin but supply-critical injectables would generate durable economics.